“Survival of patients with glioblastoma treated with standard of care is 15 months with progression free survival at 6 months (PFS-6M) of 53.9%.

“Niacin dose escalated up to 2000 mg/d is the ongoing recommended dose.”

“Interim analysis by central radiology review reported:

* INCREASE of 28% in progression free survival at 6 months (PFS-6M),
from 53.9% to 82.3% (CI95% 82.14–82.46%).”

A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma: Safety and Interim Phase II Analysis

https://www.researchsquare.com/article/rs-7889791/v1